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To the best of our knowledge, the BCL6 partner regions that we identified here have not been previously reported, with the exception of the 14q32 region. In one of two patients carrying a t(3;5)(q27;q31), a FISH control using a break-apart probe demonstrated that the BCL6 gene was probably not involved, as the break occurred telomeric to BCL6. In this case, FISH analysis did not suggest an ABR breakpoint (no faint signal from the commercial break-apart telomeric probe).
Using interphase FISH, Renné and colleagues 8 studied the involvement of immunoglobulin genes loci in 24 patients with NLPHL and found a disruption of the IgH locus in five patients. Using triple-color FISH, they identified a BCL6-IgH translocation in all five cases and conclude that this event was recurrent in NLPHL. In our series, a single t(3;14)(q27;q32) was identified by conventional cytogenetics, whereas in two cases the same translocation could only be identified by FISH and/or molecular methods, the corresponding derivative chromosomes 3 being interpreted as add(3)(q27) and t(3;6)(q27;q22), respectively. Two other rearrangements disrupting the IgH genes involved genes located in the 9q22 and 14q23 regions, respectively, indicating that BCL6 is not the only partner of IgH translocations.
Despite a long follow-up, none of our patients transformed to diffuse large B-cell lymphoma.
This study reporting the results of conventional cytogenetic investigations performed in a series of 13 NPHL patients demonstrates that in such patients, conventional karyotypic analysis is feasible, confirms the clonal nature of the tumor and provides additional informations when compared to molecular cytogenetic methods. The identification of 3q27 and 14q32 rearrangements in a mainly diploid context confirms previously published results and demonstrates that NLPHL patients share genetic defects with NHL patients rather than with CHL patients. Hematopoietic cell-specific Lyn substrate 1 (HS1, HCLS1, LckBP1) is a 75-kDa intracellular protein expressed in cells of lymphohemopoietic origin. It was originally identified in B-lymphocytes as a major substrate of B-cell receptor (BCR)-induced phosphorylation after antigen (Ag) stimulation. Genetically modified mice confirmed that in both B and T-lymphocytes HS1 is involved in the processes of Ag-receptor-induced clonal expansion and deletion. 1 However, the specific role of HS1 remained elusive. Previous studies were not unequivocal, as they suggested various possibilities including actin-binding activity, involvement in apoptosis and a nuclear function. Likewise, the subcellular localization is unclear, as HS1 was reported to be inside the nucleus, in the cytoplasm and in the lipid rafts of B-lymphocytes. The analysis of the amino-acid sequence showed that HS1 has a modular structure and is structurally related to cortactin, a cortical actin-associated protein that modulates the dynamics of the actin cytoskeleton. This structural relationship is underscored by the existence of a putative actin-binding domain at the N-terminus of HS1 molecule. Accordingly, it has been shown recently that in T-lymphocytes HS1 appears to play a non-redundant role as an actin-regulator at the immunological synapse. 2 We aimed at elucidating the subcellular localization and function of HS1 in B cells by taking advantage of our observation that HS1 is differentially expressed in distinct subsets of patients with chronic lymphocytic leukemia (CLL), 3 a malignancy characterized by the relentless accumulation of mature B cells in the peripheral blood, bone marrow and peripheral lymphoid organs. CLL cases with an aggressive behavior are characterized by the prominent expression of the phosphorylated form of HS1 while those with an indolent course tend to have HS1 mainly in the unphosphorylated form. This finding goes along the vein indicated by several studies of CLL BCR, which raise the possibility that an antigenic drive may play a role in the selection and expansion of the malignant clone. These observations are corroborated by the notion that CLL cells may show the expression of gene products associated with B-cell signaling and activation. One example is CD38, a signaling molecule that may influence the outcome of BCR signaling; another is the expression of the zeta chain-associated protein of 70 kDa (ZAP-70), a kinase that shares functions with the tyrosine kinase SYK.
By immunoprecipitation experiments and subsequent mass spectrometry analysis of the co-immunoprecipitated bands, we have investigated HS1 interactions in CLL malignant B cells and in normal human B-lymphocytes. We immunoprecipitated endogenous HS1 protein from the CLL cell line Mec-1 (Figure 1a ) and the immunoprecipitated complexes were resolved by SDS-PAGE, stained and excised from gels, reduced, alkylated and digested as described previously.
3 MS analysis confirmed the presence of immunoprecipitated HS1 in 'band c' (36 matched peptides and 54% sequence coverage) and identified a coprecipitated protein of 55 kDa as the drebrin like HIP-55, also called SH3P7, mAbp1, DBNL (10 matched peptides and 33% sequence coverage) ('band d' in Figure 1a) . Faint bands precipitated with the beads only as a control (IP-beads in Figure 1a ) and did not contain any HIP-55 sequence peptides (data not shown). To confirm the existence of the HS1/ HIP-55 complex, we performed immunoprecipitation of HS1 Figure 1b) ; conversely, we used a specific HIP-55 antibody for immunoprecipitation and analyzed the presence of coprecipitated HS1 by western blot analysis ( Figure 1b) . As shown in Figure 1b , a specific HS1/HIP-55 complex was also found in B-cell lysates obtained from leukemic B cells purified from the peripheral blood of different CLL patients. HIP-55 and HS1 were found to coimmunoprecipitate as well in different preparations of normal B-cells purified from tonsil (Figure 1c) .
To study the subcellular localization of these proteins we performed immunofluorescence analysis followed by confocal microscopy on Mec-1 cell line and CLL fresh cells. We confirmed that HS1 is a cytoplasmic molecule and we observed that it has a fiber-like organization resembling the microfilaments of polymerized F-actin cytoskeleton structures (Figure 2) . We performed immunofluorescence analysis of both HS1 and HIP-55 on the same cells by using specific antibodies conjugated with different fluorochromes. As shown in Figure 2c , the two proteins colocalized in all cells analyzed strongly suggesting that they belong to the same cytoskeleton complex. To characterize better HS1 with respect to distinct cytoskeletal components, we analyzed the localization of HS1 together with the intermediate filament protein vimentin; as shown in Figure 2b , we found that the two proteins colocalized. We next studied the relationship between HS1 and the microfilaments of polymerized F-actin, by using the specific drug phalloidin conjugated with a fluorochrome. Consistent with HS1 being a cytoskeleton component, HS1 colocalized also with actin filaments (Figure 2a) .
It is generally assumed that HS1 expression is leukocytespecific and that its homologue cortactin is expressed in epithelial cells. HS1 and cortactin belong to the same gene family and are structurally related. However, by public NCBI database searches, we found cortactin mRNA expression in different lymphoid populations (expression profile suggested by analysis of EST counts: http://www.ncbi.nlm.nih.gov/UniGene/ ESTProfileViewer.cgi?uglist ¼ Hs.632133). We performed expression analysis of cortactin mRNA and protein levels in different B-cell types. Mec-1 cell line, tonsillar B cells and some but not all CLL cells obtained from patients express different levels of cortactin mRNA (data not shown). We next analyzed the expression of the corresponding protein by immunoblot analysis in Mec-1 cell line, B-cells from CLL patients and normal B-lymphocytes from tonsil as shown in Figure 1d , the different B-cell types analyzed also expressed cortactin protein. Given the structural similarity between HS1 and cortactin and their coexpression, we asked if they might also interact; we verified that cortactin was detectable in the complex (Figure 1d) .
We next analyzed Mec-1 cells by immunofluorescence analysis followed by confocal microscopy after staining with HS1 and cortactin antibodies. As shown in Figure 2d , the two proteins colocalized at least in certain subcellular regions while in others the expression of HS1 and cortactin was mutually Letters to the Editor exclusive, suggesting that even if the two proteins might interact, they may also play distinct roles within the same cell.
Considering that HIP-55 was found to interact with the kinase ZAP-70 in T-lymphocytes, 4 and that a subset of CLL patients express ZAP-70 in their leukemic B-cells, 5 we asked whether the two proteins might interact in CLL cells. We analyzed fresh cells from both ZAP-70-negative and ZAP-70-positive patients (CLL#5 and CLL#6 in Figure 1 ). We immunoprecipitated endogenous HIP-55 protein with a specific monoclonal antibody and searched for the presence of coimmunoprecipitated ZAP-70 by immunoblot. As shown in Figure 1e , HIP-55 and ZAP-70 coimmunoprecipitated only from ZAP-70-positive cells.
In this work, we have identified novel endogenous protein complexes in human normal and leukemic B-lymphocytes. HS1, HIP-55, cortactin and ZAP-70 take part in the formation of these complexes that may be involved in the regulation of B-cell cytoskeleton. HIP-55 is coupled to the signal transduction pathway triggered by the stimulation of the antigen receptors in B and T cells. 6 In a similar manner, HS1 was shown to be involved in antigen-receptor induced clonal expansion and deletion of B-and T-lymphocytes and to play a role as an actin regulator at the T-cell immunological synapse. 2 The interaction we have observed in B cells support the possibility that HS1 and HIP-55 may have a coordinated role in coupling antigenreceptor induced signaling with cytoskeleton regulation in normal and leukemic B-cells. HIP-55 was reported to interact with and to be phosphorylated by the tyrosine kinase ZAP-70 after antigen stimulation in T-lymphocytes. 4 This is of particular interest considering that ZAP-70 is expressed at low levels also in human B-lymphocytes and is upregulated by antigen-like stimulation 7 and that its expression has been shown to predict an aggressive course in CLL patients. 8 The interaction between HIP-55 and ZAP-70 we have observed in CLL cells suggests that HIP-55 may represent a molecular link between upstream antigen-receptor-specific kinases and HS1 in leukemic B-lymphocytes cells. In addition, it indicates that the kinase ZAP-70 may have additional roles, one possibility being its involvement in the cytoskeleton regulation. Cortactin is a cytoskeleton-associated protein that is amplified and overexpressed in human carcinomas where it plays an important role in organizing the cells cytoskeleton and adhesion structures. The expression of cortactin in human lymphocytes was not addressed previously as HS1 was generally assumed to be the leukocyte-specific homologue of cortactin and it was inferred that the expression of the two proteins was mutually exclusive. Along this line, it has also been reported that cortactin is not expressed in T-lymphocytes. 2 However, our data show that cortactin mRNA and protein are expressed by distinct human B-lymphocyte populations at different levels.
By and large our observations suggest that HS1 interaction with both HIP-55 and cortactin adapters may play a role in cytoskeleton organization in B-cell types and make it tempting to speculate that the presence of different levels of cortactin and the balance between HS1, HIP-55 and ZAP-70 may regulate F-actin polymerization in normal and leukemic B-lymphocytes.
